Beyond Air Net Debt/FCF

What does Beyond Air do? Beyond Air, Inc. develops medical devices and biopharmaceuticals focused on nitric oxide (NO) delivery systems. The company's primary product, the Beyond Air NOGDS, delivers precise NO dosages to treat conditions like persistent pulmonary hypertension of the newborn (PPHN), bronchiolitis (BRO), and nontuberculous mycobacteria (NTM). Beyond Air- PH, Beyond Air- BRO, and Beyond Air- NTM are the branded product lines targeting these specific medical conditions. The company operates as a clinical-stage firm, meaning it is still in the development phase before full commercialization. Beyond Air's revenue streams come from potential future sales of its NOGDS system and branded product lines once regulatory approvals are secured. The target customers are hospitals and healthcare providers treating newborns with PPHN, pediatric patients with bronchiolitis, and patients with NTM infections. The company's focus on clinical development positions it to serve these specialized medical segments once its products are approved for market use. The firm's business model relies on securing regulatory approvals for its NO delivery system before generating revenue through product sales. It does not currently have commercialized products, so it is not yet generating revenue from its branded offerings. The company's clinical-stage status means it is still developing its products rather than selling them to end users. Beyond Air is one of the most popular companies on Eulerpool.